Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 4/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18471336 | 0.93 | SLC34A2 (0.49) | SLC34A2BRAFRAF1ABL1BCR | |
| SCHEMBL45213 | 0.92 | SLC34A2 (0.48) | SLC34A2BRAFRAF1ABL1BCR | |
| SCHEMBL15432502 | 0.90 | SLC34A2 (0.52) | SLC34A2BRAFRAF1ROCK2ROCK1 | |
| SCHEMBL15444458 | 0.90 | SLC34A2 (0.47) | SLC34A2BRAFRAF1ROCK2ROCK1 | |
| SCHEMBL46687 | 0.89 | SLC34A2 (0.48) | SLC34A2BRAFRAF1POLBLMNA | |
| SCHEMBL39860 | 0.88 | SLC34A2 (0.53) | SLC34A2BRAFRAF1LMNAROCK2 | |
| SCHEMBL46684 | 0.87 | SLC34A2 (0.47) | SLC34A2BRAFRAF1POLBLMNA | |
| SCHEMBL5999588 | 0.87 | MRGPRX2 (0.46) | SLC34A2BRAFRAF1KDM4E | |
| SCHEMBL46689 | 0.87 | MRGPRX2 (0.46) | SLC34A2BRAFRAF1KDM4E | |
| SCHEMBL39979 | 0.87 | SLC34A2 (0.53) | SLC34A2BRAFRAF1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | SLC34A2 1/4885BRAF 3436/4885RAF1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.